- 300 Million Doses of Oxfords and AstraZeneca’s AZT1222. COST-$1.2 Billion for 300 Million Doses.
- 100 Million Doses of PFIZER AND BIONTECH’s BNT162. With an agreement to possibly buy an additional 500 Million Doses. COST-$1.95 Billion for 1st 100 Million.
- 100 Million Doses of Moderna’s mRNA-1273. With an agreement to buy an additional 400 Million Doses. COST-$1.53 Billion for 1st 100 Million Doses.
- 100 Million Doses of Johnson & Johnson’s Ad26.COV2-S. With an agreement to purchase an additional 200 Million Doses. COST-$1.456 Billion for 1st 100 Million Doses.
- 100 Million Doses-The U.S. announced Friday it will pay drugmaker Sanofi and GlaxoSmithKline up to $2.1 billion to develop and deliver 100 million doses of their potential vaccine. COST-$2.1 Billion.
- U.S. Government giving NOVAVAX $1.6 Billion for 100 Million Doses of an undetermined COVID Vaccine?
- Grand Total-$9.836 Billion for 800 Million Doses. ***With Options to buy another 1.1 Billion Doses. Some Vaccines require One Shot, then 2nd Shot in 28 Days. Some Vaccines have not begun Phase I Testing. Some are entering Phase III Testing.
- America could see Vaccines available as EARLY as October of this year. With an EXTREME outbreak of Cases and Deaths, the FDA at that point might make a Vaccine Candidate available on an EMERGENCY USE ONLY Basis. I still like Oxfords and now with AstraZeneca’s manufacturing capabilities, this could be a good Choice. It addresses Two things in its Vaccine.
- May 12: DoD and HHS announced a $138 million contract with ApiJect for more than 100 million prefilled syringes for distribution across the United States by year-end 2020, as well as the development of manufacturing capacity for the ultimate production goal of over 500 million prefilled syringes in 2021.
- June 9: HHS and DoD announced a joint effort to increase domestic manufacturing capacity for vials that may be needed for vaccines and treatments:
- $204 million to Corning to expand the domestic manufacturing capacity to produce an additional 164 million Valor Glass vials each year if needed.
- $143 million to SiO2 Materials Science to ramp up capacity to produce the company’s glass-coated plastic container, which can be used for drugs and vaccines.
How is this being funded?
Congress has directed almost $10 billion to this effort through supplemental funding, including the CARES Act. Congress has also appropriated other flexible funding. The almost $10 billion specifically directed includes more than $6.5 billion designated for countermeasure development through BARDA and $3 billion for NIH research.